Therefore, the potential therapeutic strategy for obesity-related OA could be by inhibiting the leptin signal via the reduction of leptin levels and enhancement of SOCS3 expression, or by directly suppressing TLR4 expression. The gene discussed is SOCS3; the disease is obesity due to melanocortin 4 receptor deficiency.